Key facts
- It has raised $10.0M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Jul 2019.
- Ally Therapeutics has filed 1 Form D with the SEC, most recently Aug 2019 ($10.0M sold to 3 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Ally Therapeutics
Create free account
No card required
Funding rounds
2 roundsJan 2018Accelerator/Incubator—▮
About Ally Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Ally Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Ally Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Ally Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.